UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): May 7, 2013

 

Novavax, Inc.

(Exact name of registrant as specified in its charter)

         
Delaware   0-26770   22-2816046
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

     
9920 Belward Campus Drive, Rockville, MD   20850
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (240) 268-2000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 7, 2013, Novavax, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2013 and conducted a previously announced, publicly available conference call to discuss those results as well as to provide an update on the status of the Company's business operations.

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

     
Exhibit No.   Description
     
99.1   Press Release of the Company dated May 7, 2013.

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
May 7, 2013 Novavax, Inc.
  
     
     
  /s/ John A. Herrmann III, J.D.  
  Name:   John A. Herrmann III, J.D.  
  Title:   Vice President, General Counsel & Corporate Secretary  

 

 
 

 

Exhibit Index

     
Exhibit    
Number   Description
     
99.1   Press Release of the Company dated May 7, 2013.